Supernus Q4 revenue up 21% to $211.6 million, but posts $4.1 million net loss
Supernus reported fourth-quarter and full-year 2025 results and issued 2026 guidance in a press release furnished as Exhibit 99.1. Revenue grew, but the company swung to a net loss, driven mainly by higher selling, general and administrative expenses, including about $72.9 million of Sage acquisition-related costs in 2025. The 2026 outlook projects total revenues of $840 million to $870 million and GAAP operating earnings of $0 to $30 million.
Key points
- Q4 2025 total revenues were $211.6 million, up 21% from $174.2 million; full-year 2025 revenues were $719.0 million, up 9%.
- Q4 2025 net loss was $4.1 million, or $0.07 per diluted share, versus net earnings of $15.3 million, or $0.27, a year earlier; full-year net loss was $38.6 million, or $0.68 per share.
- 2026 guidance: total revenues of $840 million to $870 million, GAAP operating earnings of $0 to $30 million, and adjusted operating earnings (non-GAAP) of $140 million to $170 million.
- ONAPGO new patient initiation resumed in the first quarter of 2026; Q4 2025 ONAPGO net sales were $8.9 million.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 24, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.